155 related articles for article (PubMed ID: 15668727)
1. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).
Barrero FJ; Ampuero I; Morales B; Vives F; de Dios Luna Del Castillo J; Hoenicka J; García Yébenes J
Pharmacogenomics J; 2005; 5(2):135-41. PubMed ID: 15668727
[TBL] [Abstract][Full Text] [Related]
2. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease.
Mössner R; Henneberg A; Schmitt A; Syagailo YV; Grässle M; Hennig T; Simantov R; Gerlach M; Riederer P; Lesch KP
Mol Psychiatry; 2001 May; 6(3):350-2. PubMed ID: 11326308
[TBL] [Abstract][Full Text] [Related]
3. Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes.
Kiferle L; Ceravolo R; Petrozzi L; Rossi C; Frosini D; Rocchi A; Siciliano G; Bonuccelli U; Murri L
Neurosci Lett; 2007 Jul; 422(3):228-31. PubMed ID: 17614196
[TBL] [Abstract][Full Text] [Related]
4. Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?
Pålhagen SE; Carlsson M; Curman E; Wålinder J; Granérus AK
Acta Neurol Scand; 2008 May; 117(5):295-304. PubMed ID: 18279483
[TBL] [Abstract][Full Text] [Related]
5. [Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis].
Storch A; Ebersbach G; Fuchs G; Jost WH; Odin P; Reifschneider G; Bauer M
Fortschr Neurol Psychiatr; 2008 Dec; 76(12):715-24. PubMed ID: 19012223
[TBL] [Abstract][Full Text] [Related]
6. A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females.
Lin JJ; Chen CH; Yueh KC; Chang CY; Lin SZ
Parkinsonism Relat Disord; 2006 Jan; 12(1):9-13. PubMed ID: 16337421
[TBL] [Abstract][Full Text] [Related]
7. The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain.
Ramil E; Sánchez AJ; González-Pérez P; Rodríguez-Antigüedad A; Gómez-Lozano N; Ortiz P; Arroyo R; De las Heras V; Vilches C; García-Merino A
Mult Scler; 2010 Feb; 16(2):139-46. PubMed ID: 20007426
[TBL] [Abstract][Full Text] [Related]
8. Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease.
Gao L; Díaz-Corrales FJ; Carrillo F; Díaz-Martín J; Caceres-Redondo MT; Carballo M; Palomino A; López-Barneo J; Mir P
Acta Neurol Scand; 2010 Jul; 122(1):41-5. PubMed ID: 20085561
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.
Goldman JG; Goetz CG; Berry-Kravis E; Leurgans S; Zhou L
Arch Neurol; 2004 Aug; 61(8):1280-4. PubMed ID: 15313848
[TBL] [Abstract][Full Text] [Related]
10. Association of tau gene polymorphism with Parkinson's disease.
Zappia M; Annesi G; Nicoletti G; Serra P; Arabia G; Pugliese P; Messina D; Caracciolo M; Romeo N; Annesi F; Pasqua AA; Spadafora P; Civitelli D; Romeo N; Epifanio A; Morgante L; Quattrone A
Neurol Sci; 2003 Oct; 24(3):223-4. PubMed ID: 14600827
[TBL] [Abstract][Full Text] [Related]
11. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene.
Gadzicki D; Müller-Vahl K; Stuhrmann M
Mol Cell Probes; 1999 Aug; 13(4):321-3. PubMed ID: 10441206
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients.
Bialecka M; Klodowska-Duda G; Kurzawski M; Slawek J; Gorzkowska A; Opala G; Bialecki P; Sagan L; Droździk M
Parkinsonism Relat Disord; 2008 Dec; 14(8):636-40. PubMed ID: 18362084
[TBL] [Abstract][Full Text] [Related]
13. Association study of sporadic Parkinson's disease genetic risk factors in patients from Russia by APEX technology.
Shadrina M; Nikopensius T; Slominsky P; Illarioshkin S; Bagyeva G; Markova E; Ivanova-Smolenskaia I; Kurg A; Limborska S; Metspalu A
Neurosci Lett; 2006 Sep; 405(3):212-6. PubMed ID: 16876316
[TBL] [Abstract][Full Text] [Related]
14. No association of CNR1 gene variations with susceptibility to schizophrenia.
Seifert J; Ossege S; Emrich HM; Schneider U; Stuhrmann M
Neurosci Lett; 2007 Oct; 426(1):29-33. PubMed ID: 17881126
[TBL] [Abstract][Full Text] [Related]
15. Mortality in Parkinson's disease and its association with dementia and depression.
Hughes TA; Ross HF; Mindham RH; Spokes EG
Acta Neurol Scand; 2004 Aug; 110(2):118-23. PubMed ID: 15242420
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between polymorphic microsatellites of the VMAT2 gene and Parkinson's disease in Japan.
Kariya S; Hirano M; Takahashi N; Furiya Y; Ueno S
J Neurol Sci; 2005 May; 232(1-2):91-4. PubMed ID: 15850588
[TBL] [Abstract][Full Text] [Related]
17. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia.
Hamdani N; Tabeze JP; Ramoz N; Ades J; Hamon M; Sarfati Y; Boni C; Gorwood P
Eur Neuropsychopharmacol; 2008 Jan; 18(1):34-40. PubMed ID: 17669634
[TBL] [Abstract][Full Text] [Related]
18. The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson's disease.
Rife T; Rasoul B; Pullen N; Mitchell D; Grathwol K; Kurth J
J Neurosci Res; 2009 Aug; 87(10):2319-25. PubMed ID: 19326438
[TBL] [Abstract][Full Text] [Related]
19. Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease.
Maraganore DM; Farrer MJ; McDonnell SK; Elbaz A; Schaid DJ; Hardy JA; Rocca WA
Mov Disord; 2002 May; 17(3):509-12. PubMed ID: 12112198
[TBL] [Abstract][Full Text] [Related]
20. [The EcoR V polymorphism of human monoamine oxidase A is not associated with idiopathic Parkinson's disease in a Shanghai Han population].
Xie H; Wang X; Hao Y; Tang G; Xu L; Wu Q; Chen L; Ren D
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Aug; 19(4):329-31. PubMed ID: 12170473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
